Condition or disease | Intervention/treatment | Phase |
---|---|---|
Crohn Disease CARD9 S12N Risk Allele | Drug: Posaconazole Delayed Release Oral Tablet Drug: Matching Placebo Tablet | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Subjects will be randomly assigned to receive posaconazole or placebo in 1:1 fashion. |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Masking Description: | Both subject and clinical staff will be masked to treatment group assigned. |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease |
Estimated Study Start Date : | September 1, 2021 |
Estimated Primary Completion Date : | August 31, 2023 |
Estimated Study Completion Date : | August 31, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Posaconazole
Subjects administered posaconazole (Noxifil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
|
Drug: Posaconazole Delayed Release Oral Tablet
Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Other Name: Noxifil
|
Placebo Comparator: Placebo
Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
|
Drug: Matching Placebo Tablet
Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
|
Defined as Patient-Reported Outcome (PRO2) abdominal pain score ≤1 AND stool frequency ≤3, and Crohn's Disease Activity Index (CDAI) (<150).
PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
The CDAI is a weighted, composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more-severe disease activity.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Melissa Hampton | 310-423-0035 | melissa.hampton@cshs.org |
United States, California | |
Cedars-Sinai Medical Center (CSMC) | |
Los Angeles, California, United States, 90048 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55901 |
Principal Investigator: | Gil Y Melmed, MD | Cedars-Sinai Medical Center |
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 8, 2021 | ||||||
First Posted Date ICMJE | July 19, 2021 | ||||||
Last Update Posted Date | July 19, 2021 | ||||||
Estimated Study Start Date ICMJE | September 1, 2021 | ||||||
Estimated Primary Completion Date | August 31, 2023 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Endoscopic Response [ Time Frame: Week 12 ] Defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease.
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | No Changes Posted | ||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Pilot Study of Posaconazole in Crohn's Disease | ||||||
Official Title ICMJE | A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease | ||||||
Brief Summary | This trial is designed to evaluate the effects of oral antifungal treatment with posaconazole on active Crohn's disease (CD) activity and the burden of Malassezia spp. in CD patients with the CARD9 S12N risk allele. Further, this project will investigate the hypothesis that the microbial changes induced by antifungal treatment are associated with dampened downstream immune responses in those with a genetic predisposition to developing strong immune responses to Malassezia. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 4 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Subjects will be randomly assigned to receive posaconazole or placebo in 1:1 fashion. Masking: Triple (Participant, Care Provider, Outcomes Assessor)Masking Description: Both subject and clinical staff will be masked to treatment group assigned. Primary Purpose: Treatment
|
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Not yet recruiting | ||||||
Estimated Enrollment ICMJE |
24 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | August 31, 2024 | ||||||
Estimated Primary Completion Date | August 31, 2023 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years to 60 Years (Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
|
||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT04966585 | ||||||
Other Study ID Numbers ICMJE | MOD03104 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Responsible Party | Gil Melmed, Cedars-Sinai Medical Center | ||||||
Study Sponsor ICMJE | Cedars-Sinai Medical Center | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Cedars-Sinai Medical Center | ||||||
Verification Date | July 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |